/
GRFS
$7.10-$0.23 (-3.14%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.0B
681M shares
52-week range
$7.06 – $11.14
1% from low
Exchange
NASDAQ
ADRC
Borrow rate
0.28%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-10.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.49B | $5.10B | $5.34B | $4.93B | $6.06B | $6.59B | $7.21B | $7.23B |
| Cost of revenue | $2.44B | $2.76B | $3.08B | $2.97B | $3.85B | $4.11B | $4.42B | $4.65B |
| Gross profit | $2.05B | $2.34B | $2.26B | $1.96B | $2.21B | $2.48B | $2.79B | $2.58B |
| Gross margin | 45.7% | 45.9% | 42.2% | 39.8% | 36.5% | 37.7% | 38.7% | 35.7% |
| R&D | $240.7M | $276.0M | $294.2M | $354.9M | $361.1M | $395.3M | $384.0M | $358.3M |
| Operating income | $994.1M | $1.13B | $996.1M | $595.1M | $782.4M | $782.3M | $1.19B | $1.19B |
| EBITDA | $1.26B | $1.44B | $1.42B | $944.0M | $1.19B | $1.17B | $1.48B | $1.62B |
| Net income | $596.6M | $625.1M | $618.5M | $188.7M | $185.0M | $42.3M | $156.9M | $386.1M |
| Net margin | 13.3% | 12.3% | 11.6% | 3.8% | 3.1% | 0.6% | 2.2% | 5.3% |
| EPS (diluted) | 0.87 | 0.94 | 0.73 | 0.27 | 0.31 | 0.09 | 0.23 | 0.57 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7.8B | $0.84 | $0.82–$0.85 | 1 |
| 2027 | $8.3B | $1.09 | $1.06–$1.10 | 1 |
| 2028 | $8.7B | $1.40 | $1.37–$1.42 | 1 |
| 2029 | $9.3B | $1.56 | $1.53–$1.58 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$22.99
Price
$7.10
Implied upside
+224%
Peer comparison
Grifois, S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
www.grifols.com- Employees
- 25,247
- IPO / List date
- Jun 2, 2011
Held by traders on TradeandTell
No one on the platform currently holds GRFS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GRFS as of their last filing.
Insider activity (SEC Form 4)
Dividend history
TTM yield · 3.81% ($0.27/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-02 | $0.0945 | 2026-07-09 |
| 2025-08-12 | $0.1758 | 2025-08-20 |
Stock splits
| Execution date | Ratio |
|---|---|
| 2016-01-04 | 2-for-1 |
| 2012-12-11 | 1.05-for-1 |
| 2012-07-23 | 1-for-2reverse |
| 2011-12-01 | 11-for-10 |
Recent trades on TradeandTell
No one on the platform has traded GRFS yet.
